Leiv Lea - Corvus Pharmaceuticals Chief Officer

CRVS Stock  USD 8.95  0.01  0.11%   

Executive

Mr. Leiv Lea is Chief Financial Officer of the Company since 2015.
Age 70
Tenure 9 years
Professional MarksMBA
Address 863 Mitten Road, Burlingame, CA, United States, 94010
Phone650 900 4520
Webhttps://www.corvuspharma.com
Lea was a financial consultant from 2009 to November 2014. From 1998 to 2008, Mr. Lea served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company. From 1996 to 1997, he was a financial consultant. From 1986 to 1996, Mr. Lea served as Chief Financial Officer of Margaux, Inc., a refrigeration equipment manufacturer. He received a B.S. in Agricultural Economics from the University of California, Davis and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Corvus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.2383) % which means that it has lost $0.2383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4491) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 687.3 K in 2024.
Corvus Pharmaceuticals currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Corvus Pharmaceuticals has a current ratio of 5.68, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Corvus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Scott HarrisTerns Pharmaceuticals
N/A
Melita JungTerns Pharmaceuticals
47
Spencer JDPDS Biotechnology Corp
54
Robyn MAAcumen Pharmaceuticals
N/A
Robert ArbeitX4 Pharmaceuticals
76
John StubenrauchDay One Biopharmaceuticals
N/A
JD EsqAcumen Pharmaceuticals
53
Jeffrey JasperTerns Pharmaceuticals
N/A
Adam DubowDay One Biopharmaceuticals
57
Pamela DanagherTerns Pharmaceuticals
N/A
Mark WinderlichHookipa Pharma
38
Elly MDDay One Biopharmaceuticals
N/A
MS MBAPDS Biotechnology Corp
58
Debra SieminskiTerns Pharmaceuticals
N/A
Suba KrishnanMereo BioPharma Group
59
Pharm MPHX4 Pharmaceuticals
N/A
Soojin KimInozyme Pharma
N/A
Gayle GirondaInozyme Pharma
N/A
Diana ChungTerns Pharmaceuticals
N/A
MBA MDX4 Pharmaceuticals
62
Kirk MDPDS Biotechnology Corp
72
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. Corvus Pharmaceuticals (CRVS) is traded on NASDAQ Exchange in USA. It is located in 863 Mitten Road, Burlingame, CA, United States, 94010 and employs 28 people. Corvus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Corvus Pharmaceuticals Leadership Team

Elected by the shareholders, the Corvus Pharmaceuticals' board of directors comprises two types of representatives: Corvus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corvus. The board's role is to monitor Corvus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Corvus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corvus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Leiv Lea, Chief Officer
James MD, Senior Research
Alan Esq, Sec
MD FACP, CoFounder Director
William Jones, Vice President of Pharmaceutical Development
Erik Verner, Vice President of Chemistry Research
Jeffrey Arcara, Chief Officer
Richard MD, President, CoFounder

Corvus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corvus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.